Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.74 |
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 4/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734852 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL31358862 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL13855547 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL31711351 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL308741 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL1243678 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL2386271 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL358468 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL15986104 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL17392871 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3375883-B1 | METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE | AJINOMOTO KK (JP) | 2021-02-03 | — | — | EP | claimed |
| US-10266857-B2 | Method for producing Nε-acyl-L-lysine | AJINOMOTO CO., INC. (JP) | 2019-04-23 | — | — | US | claimed |
| EP-3375883-A1 | METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE | Ajinomoto Co., Inc. (JP) | 2018-09-19 | — | — | EP | claimed |
| EP-4626396-B1 | A PERSONAL CARE COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2026-05-20 | — | — | EP | disclosed |
| US-20260027036-A1 | A PERSONAL CARE COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| US-20250302732-A1 | BIOBASED, BIODEGRADABLE COMPOSITE POWDER FOR USE IN COSMETICS | GRANT INDUSTRIES, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-12337059-B2 | Biobased, biodegradable composite powder for use in cosmetics | GRANT INDUSTRIES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2024115001-A1 | A PERSONAL CARE COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2024-06-06 | — | — | WO | disclosed |
| CN-117616034-A | Composition for preventing or treating inflammatory bowel disease containing novel compounds | 安尼根有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-115362165-A | Antidiabetic and antiobesity composition comprising novel compounds | 安尼根有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220087928-A1 | BIOBASED, BIODEGRADABLE COMPOSITE POWDER FOR USE IN COSMETICS | GRANT INDUSTRIES, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2022061213-A1 | BIOBASED, BIODEGRADABLE COMPOSITE POWDER FOR USE IN COSMETICS | GRANT INDUSTRIES, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| EP-3375883-B1 | METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE | AJINOMOTO KK (JP) | 2021-02-03 | — | — | EP | disclosed |
| US-10786437-B2 | Composition for cosmetics and cosmetics comprising same | AJINOMOTO CO., INC (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3323868-B1 | GEL COMPOSITION CONTAINING ACYL BASIC AMINO ACID DERIVATIVE | AJINOMOTO KK (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10266857-B2 | Method for producing Nε-acyl-L-lysine | AJINOMOTO CO., INC. (JP) | 2019-04-23 | — | — | US | disclosed |
| EP-3375883-A1 | METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE | Ajinomoto Co., Inc. (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-3323868-A1 | GEL COMPOSITION CONTAINING ACYL BASIC AMINO ACID DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027036-A1 | A PERSONAL CARE COMPOSITION | IL5, C9, IL33 | NOD1 3475/4885CASP2 2801/4885GNAI3 4549/4885 |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | NOD1 333/4885CASP2 3007/4885GNAI3 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.